LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

LLY

1,011.12

+1.64%↑

JNJ

229.43

+0.85%↑

ABBV

207.16

-1.57%↓

UNH

399.42

+1.64%↑

AZN

186

+0.19%↑

Home・Elenco Azioni・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Aperta

SettoreSettore sanitario

21.45 -0.23

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.45

Massimo

21.45

Metriche Chiave
By Trading Economics
Entrata	-1.6M -21M
Vendite	14M 54M
Margine di Profitto	-39.611
Dipendenti	178
EBITDA	-3.8M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-3.62% downside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1B 2.2B
Apertura precedente	21.68
Chiusura precedente	21.45

Notizie sul Sentiment di mercato

By Acuity

50%

150 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

6.26 / 7.47 Supporto e resistenza

Day One Biopharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 mag 2026, 22:50 UTC

Utili

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mag 2026, 22:49 UTC

Utili

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mag 2026, 22:32 UTC

Utili

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mag 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mag 2026, 22:57 UTC

Discorsi di Mercato

Utili

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mag 2026, 22:26 UTC

Utili

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mag 2026, 22:25 UTC

Utili

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mag 2026, 22:24 UTC

Utili

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mag 2026, 22:23 UTC

Utili

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mag 2026, 22:19 UTC

Utili

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mag 2026, 22:14 UTC

Utili

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mag 2026, 22:13 UTC

Utili

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mag 2026, 22:12 UTC

Utili

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mag 2026, 22:11 UTC

Utili

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mag 2026, 22:11 UTC

Utili

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mag 2026, 22:10 UTC

Utili

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mag 2026, 22:09 UTC

Utili

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mag 2026, 22:08 UTC

Utili

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mag 2026, 22:07 UTC

Utili

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mag 2026, 22:06 UTC

Utili

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mag 2026, 22:05 UTC

Utili

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mag 2026, 22:04 UTC

Utili

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Confronto tra pari

Modifica del prezzo

Day One Biopharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

-3.62% in calo

Previsioni per 12 mesi

Media 20.75 USD -3.62%

Alto 21.5 USD

Basso 17 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Day One Biopharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

6.26 / 7.47Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

150 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.